Ginkgo Bioworks Holdings, INC Schedule 13G passive stakes

BlackRock, Inc. has amended its Schedule 13G filing to report its beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A Stock.

Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group regarding Ginkgo Bioworks.

The Vanguard Group has filed an amended Schedule 13G, indicating a 0% beneficial ownership in Ginkgo Bioworks Holdings Inc. following an internal realignment.

Baillie Gifford & Co. reported a 4.9% beneficial ownership stake in Ginkgo Bioworks Holdings, Inc.'s Class A Common Stock as of December 31, 2025.

Cascade Investment, L.L.C. and William H. Gates III have reported a 7.5% beneficial ownership stake in Ginkgo Bioworks Holdings, Inc., including potential earn-out shares.

The Vanguard Group has reported a 5.13% beneficial ownership stake in Ginkgo Bioworks Holdings Inc., primarily for investment purposes.

BlackRock, Inc. has disclosed a passive beneficial ownership of 6.5% of Ginkgo Bioworks Holdings, Inc.'s common stock, totaling over 3 million shares.

Austin Che, a reporting person, has filed an Amendment No. 4 to Schedule 13G, indicating he is no longer a beneficial owner of more than five percent of Ginkgo Bioworks Holdings, Inc.'s Class A Common Stock as of December 31, 2024.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.45% beneficial ownership stake in Ginkgo Bioworks Holdings Inc. as of December 31, 2024.

ARK Investment Management LLC has filed an amended Schedule 13G indicating a complete divestment of its beneficial ownership in Ginkgo Bioworks Holdings, Inc., holding 0.0% of Class A Common Stock as of September 30, 2024.